Comparison · NCT00772031-b7e360f2
Topiramate Plus Propranolol vs Topiramate Plus Placebo: Number of Subjects Experiencing at Least a 50% Reduction in 28-day Moderate to Severe Headache Days
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Topiramate Plus Propranolol vs Topiramate Plus Placebo: Number of Subjects Experiencing at Least a 50% Reduction in 28-day Moderate to Severe Headache Days. Trial comparisons, record NCT00772031-b7e360f2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00772031-b7e360f2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.31 | 0.221 | 0.415 | wilson | |
| Risk in group 2 | 0.28 | 0.195 | 0.386 | wilson | |
| Risk difference, group 1 minus group 2 | 0.029 | -0.109 | 0.165 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.1 | 0.689 | 1.77 | log | |
| Odds ratio, group 1 over group 2 | 1.15 | 0.59 | 2.24 | log | |
| Number needed to treat, for one more participant with the outcome on Topiramate Plus Propranolol than on Topiramate Plus Placebo | 34.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Topiramate Plus Propranolol | Participants will receive propranolol and topiramate. | 26 | 84 | OG000 |
| Group 2 | Topiramate Plus Placebo | Participants will receive placebo and topiramate. | 23 | 82 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Experiencing at Least a 50% Reduction in 28-day Moderate to Severe Headache Days
- Description
- Time frame
- 6 months
- Population
- All participants with the opportunity for 6-month follow-up. Due to early study termination some participants were randomized and did not have the opportunity to be followed for six months
Source ClinicalTrials.gov
Trial
- Title
- NINDS CRC Chronic Migraine Treatment Trial
- NCT number
- NCT00772031
- Phases
- PHASE3
- Conditions
- Chronic Migraine
- Interventions
- propranolol LA, topiramate, placebo
- Lead sponsor
- Anne Lindblad
- Results first posted
- 2012-01-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00772031?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00772031-b7e360f2